Cite
Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra ® ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP).
MLA
Susen, Sophie, et al. “Management of Bleeding and Invasive Procedures in Haemophilia A Patients with Inhibitor Treated with Emicizumab (Hemlibra ® ): Proposals from the French Network on Inherited Bleeding Disorders (MHEMO), the French Reference Centre on Haemophilia, in Collaboration with the French Working Group on Perioperative Haemostasis (GIHP).” Haemophilia : The Official Journal of the World Federation of Hemophilia, vol. 25, no. 5, Sept. 2019, pp. 731–37. EBSCOhost, https://doi.org/10.1111/hae.13817.
APA
Susen, S., Gruel, Y., Godier, A., Harroche, A., Chambost, H., Lasne, D., Rauch, A., Roullet, S., Fontana, P., Goudemand, J., de Maistre, E., Chamouard, V., Wibaut, B., Albaladejo, P., & Négrier, C. (2019). Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra ® ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Haemophilia : The Official Journal of the World Federation of Hemophilia, 25(5), 731–737. https://doi.org/10.1111/hae.13817
Chicago
Susen, Sophie, Yves Gruel, Anne Godier, Annie Harroche, Herve Chambost, Dominique Lasne, Antoine Rauch, et al. 2019. “Management of Bleeding and Invasive Procedures in Haemophilia A Patients with Inhibitor Treated with Emicizumab (Hemlibra ® ): Proposals from the French Network on Inherited Bleeding Disorders (MHEMO), the French Reference Centre on Haemophilia, in Collaboration with the French Working Group on Perioperative Haemostasis (GIHP).” Haemophilia : The Official Journal of the World Federation of Hemophilia 25 (5): 731–37. doi:10.1111/hae.13817.